Video

Marcelo Bigal, MD, PhD

Publish date: June 26, 2015

Dr. Bigal discusses the findings from two phase IIb clinical trials of TEV-48125, a CGRP monoclonal antibody, for the preventive treatment of chronic migraine and for high-frequency episodic migraine.


 

References

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Are Triptans Safe to Take in Pregnancy?
MDedge Neurology
Is Glutamatergic Modulation Effective Against Migraine?
MDedge Neurology
What Are the Neuropsychologic Effects of Cluster Headache?
MDedge Neurology
Postural Tachycardia Syndrome Is Common Among Migraineurs
MDedge Neurology
Updated Guideline for Acute Migraine Treatment
MDedge Neurology
Adult Migraineurs Have Atypical Correlations Between Cortical Thickness and Pain Thresholds
MDedge Neurology
Retired NFL Players Have Increased Incidence of Headache
MDedge Neurology
Migraine Treatment: Aura Status Matters
MDedge Neurology
Robert Cowan, MD
MDedge Neurology
Stewart Tepper, MD
MDedge Neurology